Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment

Anna H Turaj, MSc, Vikki L Field, Claude H.T. Chan, PhD, Christine A. Penfold, BSc, Jinny H. Kim, PhD, Sonya James, PhD, Kerry L Cox, Tibor Keler, PhD, Peter M Johnson, MA, MD, Aymen Al-Shamkhani, PhD, Stephen A Beers, PhD, Martin J. Glennie, PhD, Mark S Cragg, PhD, Sean H Lim, MD PhD

Blood (2016) 128 (22): 3024.

https://doi.org/10.1182/blood.V128.22.3024.3024

Published: 2016

Journal Articles

Influence of immunoglobulin isotype on therapeutic antibody function

Stephen A. Beers, Martin J. Glennie, Ann L. White

Blood (2016) 127 (9): 1097–1101.

https://doi.org/10.1182/blood-2015-09-625343

Published: 2016

Journal Articles

Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412

Khiyam Hussain, Chantal E. Hargreaves, Ali Roghanian, Robert J. Oldham, H. T. Claude Chan, C. Ian Mockridge, Ferdousi Chowdhury, Bjorn Frendéus, Kirsty S. Harper, Jonathan C. Strefford, Mark S. Cragg, Martin J. Glennie, Anthony P. Williams, Ruth R. French

Blood (2015) 125 (1): 102–110.

https://doi.org/10.1182/blood-2014-08-593061

Published: 2015

Includes: Supplemental data

Journal Articles

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Andrew T. Vaughan, Chisako Iriyama, Stephen A. Beers, Claude H. T. Chan, Sean H. Lim, Emily L. Williams, Vallari Shah, Ali Roghanian, Bjorn Frendéus, Martin J. Glennie, Mark S. Cragg

Blood (2014) 123 (5): 669–677.

https://doi.org/10.1182/blood-2013-04-490821

Published: 2014

Includes: Supplemental data

Journal Articles

Neutrophils: “neu players” in antibody therapy?

Stephen A. Beers, Martin J. Glennie

Blood (2013) 122 (18): 3093–3094.

https://doi.org/10.1182/blood-2013-09-525451

Published: 2013

Journal Articles

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

Sean H. Lim, Andrew T. Vaughan, Margaret Ashton-Key, Emily L. Williams, Sandra V. Dixon, H. T. Claude Chan, Stephen A. Beers, Ruth R. French, Kerry L. Cox, Andrew J. Davies, Kathleen N. Potter, C. Ian Mockridge, David G. Oscier, Peter W. M. Johnson, Mark S. Cragg, Martin J. Glennie

Blood (2011) 118 (9): 2530–2540.

https://doi.org/10.1182/blood-2011-01-330357

Published: 2011

Includes: Supplemental data

Journal Articles

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

Waleed Alduaij, Andrei Ivanov, Jamie Honeychurch, Eleanor J. Cheadle, Sandeep Potluri, Sean H. Lim, Kazuyuki Shimada, Claude H. T. Chan, Alison Tutt, Stephen A. Beers, Martin J. Glennie, Mark S. Cragg, Tim M. Illidge

Blood (2011) 117 (17): 4519–4529.

https://doi.org/10.1182/blood-2010-07-296913

Published: 2011

Includes: Multimedia, Supplemental data

Journal Articles

Non-Cognate Cytotoxic T Cells Can Be Retargeted Against CD20 Positive Tumour Cells Using [Fab' × MHC Class I/Peptide] Conjugates.

Angela D Hamblin, BA, MRCP, Ben CR King, PhD, Ruth R French, PhD, Claude H Chan, PhD, Alison L Tutt, MPhil, Philip M Savage, PhD, FRCP, Peter W Johnson, MD, FRCP, Martin J Glennie, PhD

Blood (2010) 116 (21): 2838.

https://doi.org/10.1182/blood.V116.21.2838.2838

Published: 2010

Journal Articles

Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates

Mark S. Cragg, Waleed Alduaij, Christian Klein, Pablo Umana, Martin J. Glennie, Tim M. Illidge

Blood (2010) 116 (17): 3373–3374.

https://doi.org/10.1182/blood-2010-07-291054

Published: 2010

Journal Articles

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

Stephen A. Beers, Ruth R. French, H. T. Claude Chan, Sean H. Lim, Timothy C. Jarrett, Regina Mora Vidal, Sahan S. Wijayaweera, Sandra V. Dixon, Hyungjin Kim, Kerry L. Cox, Jonathan P. Kerr, David A. Johnston, Peter W. M. Johnson, J. Sjef Verbeek, Martin J. Glennie, Mark S. Cragg

Blood (2010) 115 (25): 5191–5201.

https://doi.org/10.1182/blood-2010-01-263533

Published: 2010

Includes: Supplemental data

Journal Articles

Complement: help or hindrance?

Stephen A. Beers, Mark S. Cragg, Martin J. Glennie

Blood (2009) 114 (27): 5567–5568.

https://doi.org/10.1182/blood-2009-10-249466

Published: 2009

Journal Articles

New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma.

Waleed Alduaij, MRes, Sandeep Potluri, BA, Andrei Ivanov, PhD, Jamie Honeychurch, PhD, Stephen A Beers, PhD, Claude Chan, PhD, Kazayuki Shimada, MD, Martin J. Glennie, PhD, Mark S Cragg, PhD, Tim Illidge, MD, PhD

Blood (2009) 114 (22): 725.

https://doi.org/10.1182/blood.V114.22.725.725

Published: 2009

Journal Articles

Phase 1/2 study of fractionated 131 I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

Tim M. Illidge, Mike Bayne, Nicholas S. Brown, Samantha Chilton, Mark S. Cragg, Martin J. Glennie, Yong Du, Valerie Lewington, James Smart, James Thom, Maureen Zivanovic, Peter W. M. Johnson

Blood (2009) 113 (7): 1412–1421.

https://doi.org/10.1182/blood-2008-08-175653

Published: 2009

Journal Articles

Novel Mechanisms of Non-Apoptotic Cell Death Evoked by Type II Anti-CD20 (Tositumomab) and HLA-DR Monoclonal Antibodies

Tim Illidge, MD, PhD, Andrei Ivanov, PhD, Stephen A Beers, PhD, Claire Walshe, PhD, Claude Chan, PhD, Waleed Alduaij, Martin J. Glennie, PhD, Mark S Cragg

Blood (2008) 112 (11): 883.

https://doi.org/10.1182/blood.V112.11.883.883

Published: 2008

Journal Articles

Response: Superior B cell–depleting activity of type II anti-CD20 mAb is not due to activation of complement

Stephen A. Beers, Mark S. Cragg, Martin J. Glennie

Blood (2008) 112 (10): 4355–4356.

https://doi.org/10.1182/blood-2008-08-172999

Published: 2008

Journal Articles

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

Stephen A. Beers, Claude H. T. Chan, Sonya James, Ruth R. French, Kathrine E. Attfield, Claire M. Brennan, Anupama Ahuja, Mark J. Shlomchik, Mark S. Cragg, Martin J. Glennie

Blood (2008) 112 (10): 4170–4177.

https://doi.org/10.1182/blood-2008-04-149161

Published: 2008

Includes: Supplemental data

Journal Articles

Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation

Ruth R. French, Vadim Y. Taraban, Graham R. Crowther, Tania F. Rowley, Juliet C. Gray, Peter W. Johnson, Alison L. Tutt, Aymen Al-Shamkhani, Martin J. Glennie

Blood (2007) 109 (11): 4810–4815.

https://doi.org/10.1182/blood-2006-11-057216

Published: 2007

Includes: Supplemental data

Journal Articles

Cyclophosphamide Induced CD11b + Cells Can Inhibit Anti-CD40 Monoclonal Antibody (mAb) Therapy of B-Cell Lymphoma.

Jamie Honeychurch, PhD, Martin J. Glennie, PhD, Peter W. Johnson, MD, Tim M. Illidge, MD, PhD

Blood (2004) 104 (11): 3280.

https://doi.org/10.1182/blood.V104.11.3280.3280

Published: 2004

Journal Articles

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells

Mark S. Cragg, Mike B. Bayne, Alison L. Tutt, Ruth R. French, Stephen Beers, Martin J. Glennie, Timothy M. Illidge

Blood (2004) 104 (8): 2540–2542.

https://doi.org/10.1182/blood-2004-05-1733

Published: 2004

Journal Articles

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

Jessica L. Teeling, Ruth R. French, Mark S. Cragg, Jeroen van den Brakel, Marielle Pluyter, Haichun Huang, Claude Chan, Paul W. H. I. Parren, C. Erik Hack, Michael Dechant, Thomas Valerius, Jan G. J. van de Winkel, Martin J. Glennie

Blood (2004) 104 (6): 1793–1800.

https://doi.org/10.1182/blood-2004-01-0039

Published: 2004

NARROW

Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment

Influence of immunoglobulin isotype on therapeutic antibody function

Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Neutrophils: “neu players” in antibody therapy?

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

Non-Cognate Cytotoxic T Cells Can Be Retargeted Against CD20 Positive Tumour Cells Using [Fab' × MHC Class I/Peptide] Conjugates.

Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

Complement: help or hindrance?

New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma.

Phase 1/2 study of fractionated 131 I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

Novel Mechanisms of Non-Apoptotic Cell Death Evoked by Type II Anti-CD20 (Tositumomab) and HLA-DR Monoclonal Antibodies

Response: Superior B cell–depleting activity of type II anti-CD20 mAb is not due to activation of complement

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation

Cyclophosphamide Induced CD11b + Cells Can Inhibit Anti-CD40 Monoclonal Antibody (mAb) Therapy of B-Cell Lymphoma.

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only